Total
0
Shares
Cardiol Therapeutics Inc. (TSX:CRDL) upsizes bought deal public offering
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cardiol Therapeutics Inc. (CRDL) has agreed to increase the size of its bought deal offering
  • The underwriters, led by Raymond James Ltd. have agreed to purchase 6,112,000 units of the company at a price of $3.60 per unit
  • Aggregate gross proceeds from the offering will total approximately $22 million
  • The offering is expected to close on or about May 12, 2021
  • Cardiol Therapeutics is a clinical-stage biotechnology company focused on anti-inflammatory therapies for the treatment of cardiovascular disease
  • Cardiol Therapeutics (CRDL) is down 13.78 per cent, trading at C$3.38 per share at 9:45 am ET

Cardiol Therapeutics Inc. (CRDL) has agreed to increase the size of its previously announced $15 million bought deal offering.

Pursuant to the upsized deal terms, the underwriters, led by Raymond James Ltd. as sole bookrunner, have agreed to purchase 6,112,000 units of the company at a price of $3.60 per unit. Aggregate gross proceeds from the offering will total approximately $22 million.

Each unit comprises one common share and one-half common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share for $4.60 for a period of 36 months following the closing of the offering.

The underwriters have been granted an over-allotment option to purchase up to the equivalent of 15 per cent of the number of units sold pursuant to the offering. The underwriters can elect to exercise the over-allotment option for units, warrants, or any combination thereof.

Net proceeds will be used to advance the company’s research and clinical development programs, fund additional commercial product development, and for general corporate purposes.

The offering is expected to close on or about May 12, 2021, and is subject to the approval of the Toronto Stock Exchange, and the entering into of an underwriting agreement between the company and the underwriters.

Cardiol Therapeutics is a clinical-stage biotechnology company focused on anti-inflammatory therapies for the treatment of cardiovascular disease.

Cardiol Therapeutics (CRDL) is down 13.78 per cent, trading at C$3.38 per share at 9:45 am ET.

More From The Market Herald
HempFusion (TSX:CBD.U) announces US$2M private placement

" HempFusion (TSX:CBD.U) increases private placement

HempFusion Wellness (CBD.U) has increased the size of its previously announced non-brokered private placement to over US$2,500,000.
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
American Pacific Mining - President, Eric Saderholm. - The Market Herald Canada

" American Pacific Mining (CSE:USGD) reports bonanza-grade gold and silver

American Pacific (USGD) has doubled the size of its Tuscarora Property and reported bonanza-grade samples of gold and silver.